AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 5 added, 3 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $140.43
- 52-wk high
- $174.13
- High
- $142.37
- 52-wk low
- $130.96
- Low
- $139.27
- Prev close
- $141.51
- Mkt cap
- $38.99B
- P/E
- 13.5x
- Volume
- 2.59M
- Fwd P/E
- 11.9x
- Beta
- 1.37
- Div yield
- 1.26%
- P/S
- 1.2x
- P/B
- 1.6x
- Profit margin
- +9.2%
- Op margin
- +13.0%
- ROE
- +12.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about DHI filings
Are insiders buying or selling DR Horton Inc (DHI) stock?
Neither. DR Horton Inc (DHI) insiders filed no open-market purchases or sales in the 90 days to Oct 1, 2026, according to SEC Form 4 filings.
Which members of Congress have traded DHI recently?
None. No member of Congress disclosed a DHI trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this DHI smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position.
What funds are doing
Buys/Adds (3)
- TS
Two Sigma
$107.1M
added
- CI
Citadel
$80.9M
added
- BA
Balyasny
$64.1M
added
How top traders are positioned
No tracked top-trader positions in DHI right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 7.0% above what analysts expected.
Earnings per share
$2.99 expected
Revenue
No comparable estimate
FY2026 guidance
$32.50B to $33.00B
No comparable estimate
Reports Oct 27, 2026, in 26 days
Estimates as of Oct 1, 2026
EPS expected
$2.80 to $3.14
Revenue expected
12 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $9.68B | $6.89B | $7.56B | $9.23B |
| Cost of what it sold | $7.58B | $5.29B | $5.85B | $7.08B |
| Gross profit | $2.10B | $1.59B | $1.70B | $2.15B |
| What it spent | ||||
| Sales and admin | $970.9M | $865.1M | $903.3M | $991.2M |
| Other operating costs | — | — | — | -$71.2M |
| Total operating expenses | $970.9M | $865.1M | $903.3M | $920.0M |
| What was left | ||||
| Operating profit | $1.13B | $729.6M | $800.0M | $1.23B |
| Interest on debt | — | $31.3M | $60.0M | — |
| Profit before tax | $1.20B | $798.1M | $867.4M | $1.23B |
| Tax | $288.0M | $203.3M | $209.4M | $307.5M |
| Net profit | $905.3M | $594.8M | $647.9M | $904.9M |
| EBITDA | $1.23B | $857.1M | $760.7M | $1.26B |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
15 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace